Trial Profile
A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Diffuse scleroderma; Interstitial lung diseases; Systemic scleroderma
- Focus Registrational; Therapeutic Use
- Acronyms SENSCIS
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- 15 Nov 2023 Results of post-hoc analysis assessing whether participants with ACA or ARA experience progression of SSc-ILD presented at the ACR Convergence 2023
- 15 Nov 2023 Results (n=120) assessing absolute changes in nailfold videocapillaroscopy (NVC) measures in a sub-study of this trial presented at the ACR Convergence 2023
- 15 Nov 2023 Results of pooled SENSCIS and SENSCIS -ON trials, presented at the ACR Convergence 2023